Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

NCT03913130 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT03913130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Lead sponsor
Laboratoires Thea
Phase
Phase 1/2
Overall status
Terminated
Start date
May 13, 2019
Completion date
October 3, 2022
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

blindness, eye diseases, eye diseases, hereditary, eye disorders congenital, leber congenital amaurosis, leber congenital amaurosis 10, neurologic manifestations, retinal disease, sensation disorders, vision disorders